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Abstract
Background: Interventions that reduce exposure to malaria infection may lead to delayed malaria morbidity and mortality.
We investigated whether intermittent preventive treatment of malaria in children (IPTc) was associated with an increase in
the incidence of malaria after cessation of the intervention.
Methods: An individually randomised, trial of IPTc, comparing three courses of sulphadoxine pyrimethamine (SP) plus
amodiaquine (AQ) with placebos was implemented in children aged 3–59 months during the 2008 malaria transmission
season in Burkina Faso. All children in the trial were given a long lasting insecticide treated net; 1509 children received
SP+AQ and 1505 received placebos. Passive surveillance for malaria was maintained until the end of the subsequent malaria
transmission season in 2009, and active surveillance for malaria infection, anaemia and malnutrition was conducted.
Results: On thousand, four hundred and sixteen children (93.8%) and 1399 children (93.0%) initially enrolled in the
intervention and control arms of the trial respectively were followed during the 2009 malaria transmission season. During
the period July 2009 to November 2009, incidence rates of clinical malaria were 3.84 (95%CI; 3.67–4.02) and 3.45 (95%CI;
3.29–3.62) episodes per child during the follow up period in children who had previously received IPT or placebos,
indicating a small increase in risk for children in the former intervention arm (IRR = 1.12; 95%CI 1.04–1.20) (P = 0.003).
Children who had received SP+AQ had a lower prevalence of malaria infection (adjusted PR: 0.88 95%CI: 0.79–0.98) (P = 0.04)
but they had a higher parasite density (P = 0.001) if they were infected. There was no evidence that the risks of moderately
severe anaemia (Hb,8 g/dL), wasting, stunting, or of being underweight in children differed between treatment arms.
Conclusion: IPT with SP+AQ was associated with a small increase in the incidence of clinical malaria in the subsequent
malaria transmission season.
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Introduction
Intermittent preventive treatment (IPT) of malaria is a
promising strategy for malaria control in infants and young
children. Meta analysis indicates a 30% (95%CI: 20-39) protective
efficacy in infants against clinical malaria [1]. Studies conducted in
older children living in areas where malaria transmission is highly
seasonal have reported 67% to 86% reductions in clinical malaria
[2–4]. These initial trials were conducted in communities where
the use of insecticide treated bednets (ITNs) was low. More
recently, trials of IPT in children who were sleeping under a long
lasting insecticide treated net (LLIN) showed a protective efficacy
against clinical episodes of malaria of 70% in Burkina Faso [5] and
83% Mali [6], indicating that IPT provides substantial additional
protection to that offered by ITNs.
Interventions which reduce exposure to malaria could interfere
with the development of acquired immunity which could, in turn,
lead to a shift of morbidity and mortality from malaria from
younger to older age groups (‘‘rebound effect’’) [7]. Early studies in
African children which employed chemoprophylaxis showed a
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significant increase in cases of clinical malaria when the
intervention was stopped. In The Gambia, children who had
received seasonal chemoprophylaxis from the age of three months
to five years had a significant increase in clinical episodes of
malaria in the year after chemoprophylaxis was stopped. No
increase in mortality was observed but the trial was only large
enough to have detected a substantial effect [8]. In Tanzania,
administration of chemoprophylaxis during the first year of life led
to a significant increase in the risk of malaria and anaemia during
the second year of life [9]. By the age of five years the cumulative
incidence of clinical attacks of malaria was similar in the
intervention and control groups [10].
One of the rationales underlying the development of IPT as a
malaria control tool is that by allowing some infections to occur
between drug administrations, it is less likely than chemoprophy-
laxis to interfere with the development of naturally acquired
immunity to malaria. Therefore, a number of studies have
examined the malaria experience of infants in the year after they
had received IPT (IPTi). In the initial study of IPTi undertaken in
Tanzania [11], the investigators found that, protection appeared
to persist into the second year of life with a 35% reduction in the
incidence of clinical malaria in children who had previously
received IPTi. However, a sustained protective effect has not been
seen in subsequent studies. A suggestion of an increased risk of
high density infections and of anaemia was found in two studies
undertaken in Ghana [12,13]. A meta analysis of all IPTi trials did
not find clear evidence of an increase in the incidence of clinical
attacks of malaria or of anaemia in the year following the
intervention [1].
Only limited information is available as to whether administra-
tion of IPT to older children is associated with an increased risk of
malaria in the period following the intervention. No overall
increase in risk was observed in Senegal and Mali [2,3] with
incidence rate ratios (IRR) of 0.98 (95%CI: 0.82–1.17) and 1.07
(95%CI: 0.90–1.27) respectively. No significant overall increase
(IRR=1.38; 95%CI: 0.98–2.16; p = 0.059) in the subsequent
malaria transmission season was observed in Ghana in children
who received AS+AQ monthly [4]. A meta-analysis of available
data on IPT in children found only weak evidence (IRR=1.11;
95%CI 0.99–1.24; P= 0.07) of an increase in the incidence of
malaria in the year post intervention [14]. Because of the paucity
of information on the longer term impact of IPTc, we studied the
subsequent malaria experience of Burkinabe children who
received IPTc for one transmission season.
Methods
The original protocol for this trial (Protocol S1), the amended
protocol (Protocol S2) and supporting CONSORT checklist
(Checklist S1) are available as supporting information.
Ethical approval to conduct the trial was obtained from the
health ethics committee of Burkina Faso and from the London
School of Hygiene and Tropical Medicine ethics committee
(Ethics S1). Meetings were held with local health authorities and
the communities to explain the objectives and methods of the
study. Written informed consent was obtained from caregivers of
children before enrolment into the trial and an independent Data
Safety and Monitoring Board (DSMB) monitored the trial.
Study area and population
The study was conducted from August 2008 to November 2009
in Bousse´ health district, in central Burkina Faso. Four villages
(Laye, Niou, Sao and Toeghin) which each have a health centre
were included. Malaria transmission in the study area is high and
seasonal with most of the transmission occurring between July and
October. Children aged 3–59 months residing in the study villages
were enrolled. Details of the study area have been published
previously [5].
Study design
An individually randomised, double-blind, placebo-controlled
trial of intermittent preventive treatment of malaria was conducted
during the malaria transmission season of 2008; 3014 children
were enrolled after screening. All children were given a long
lasting insecticide treated net (LLIN) (PermaNetH; www.vester-
gaard-frandsen.com); 1509 children were randomly assigned to
receive IPT with sulphadoxine/pyrimethamine (SP) plus amodi-
aquine (AQ) and 1505 were randomised to receive placebos. SP
was given as single dose of 25 mg per kg of sulphadoxine plus
1.25 mg of pyrimethamine and AQ was given for 3 days as a daily
dose of 10 mg per kg. Three rounds of IPTc were given starting in
August 2008 with a one-month interval between treatments.
Details of the eligibility, randomisation and intervention proce-
dures have been presented elsewhere [5]. The intervention ended
after the third course of IPT but children were followed up to the
end of the subsequent malaria transmission season. The main
outcome measure of the study reported in this paper is the
incidence of malaria in the malaria transmission season after
cessation of the intervention (2009).
Surveillance of malaria episodes
Passive surveillance for malaria episodes was set up from the day
of administration of the first dose of IPT in July 2008 until the end
of November 2009. Briefly, caregivers were advised to bring their
children to the village health centre at anytime if they were sick.
Clinical examination was performed by a nurse. Caregivers were
asked if the child had had fever in the previous 24 hours, axillary
temperature was measured and signs and symptoms of illness were
recorded. A rapid malaria diagnosis test (RDT) was performed
and thick and thin blood films were prepared if a child had fever
or a history of fever.
Children with a positive RDT who were thought to have
uncomplicated malaria were treated with artesunate plus amodi-
aquine (AS+AQ) or artemether lumethantrine (CoartemH) at the
health centre. If a child had signs or symptoms of severe malaria,
treatment with quinine was provided and, when required, the
child was referred to the district hospital in keeping with local
guidelines. Children with an illness other than malaria were given
appropriate treatment free of charge. Hospital admissions due to
malaria and other causes were recorded and children’s condition
was monitored until release from the health centre.
Monitoring of malaria infection, anaemia and nutrition
From July 2009 to November 2009, weekly home visits were
made to monitor the prevalence of malaria infection. Each week,
150 children per treatment arm were randomly selected for a
home visit. A history of fever in the previous 24 hours was
recorded, axillary temperature was measured and thin and thick
blood films were prepared for all children. During home visits,
caregivers of children were asked if the LLIN allocated to the child
was still in the house and whether the child had slept under the net
the previous night.
At the end of the 2009 malaria transmission season, we
performed a cross-sectional survey of all children from the original
trial who were available. Children had a clinical examination
performed by study medical staff. Caregivers were asked if their
child had fever within the previous 24 hours and axillary
temperature was measured. Thick and thin blood films and filter
IPT in Children and Rebound Malaria Morbidity
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paper blood spots were prepared and haemoglobin concentration
was measured. Children’s weight and height were recorded.
During these surveys, a rapid malaria diagnostic test (RDT) was
performed on the spot if a child had fever or a history of fever. If
the RDT test was positive and the child was suspected of having
uncomplicated malaria, s/he was referred to health centre for
appropriate treatment with AS+AQ or CoartemH. Children with
severe malaria or an illness other than malaria were treated as
described in the previous section. Details of the procedures used
during these surveys have been presented previously [5].
Laboratory methods
Thick and thin blood films were air-dried and stained with 5%
Giemsa and read independently by two laboratory technicians.
The parasite count was measured against 200 white blood cells
(WBC) and converted to a parasite density per ml assuming that
1 mL of blood contains 8000 WBC per mL. In the event of a
discrepancy between the two readers, the slide was re-examined by
a third laboratory technician. The arithmetic mean of the 2
readings was used as the final parasite density if there was
agreement between two of readers. If there was no agreement after
the third reading, the arithmetic mean of the three parasite
densities was used.
Haemoglobin concentration was determined using a HemocueH
321 (Hemocue AB, Angelholm, Sweden) as described previously [5].
Sample size and power
The sample size for the first phase of the study was set to detect a
20% reduction in the incidence of clinical malaria and a 50%
reduction in the incidence of admissions to hospital for severe
Figure 1. Study profile.
doi:10.1371/journal.pone.0023391.g001
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malaria in children who had received intermittent preventive
treatment. Details regarding sample size calculation for the main
study have been published elsewhere (Konate´ et al., 2010). Based on
the requirements set out above, at least 1500 children were needed
per treatment arm for the study to have a 90% power to detect
reductions in the endpoint mentioned above. Thus, 1509 and 1505
children were enrolled and randomized to receive SP+AQ or
placebos respectively. It was anticipated that there would be a 10%–
20% of loss to follow-up in the second year. Therefore, it was
estimated that with this sample size, the study would have greater
than 90% power to detect a 20% increase in the incidence of clinical
malaria and greater than 90% power to detect a 20% increase in
parasite prevalence in subsequent high malaria transmission season
post intervention in children who received IPT with SP+AQ.
Data handling and analysis
Data entry was performed by two independent data clerks
using Microsoft ACCESS and analyses were performed using
STATA version 11 (www.stata.com). The intervention period
was defined as the period from the first dose of IPT
administration to the end of November 2008 (42 days after
the third dose of IPT). The post intervention high malaria
transmission period was defined as the period from July to
November 2009 and the whole post intervention period was
defined as the period from December 2008 to November 2009,
which included the low malaria transmission season dry season
(December 2008 to June 2009). Children were grouped in two
age categories for adjusted analyses: children aged 3 to 23
months and children aged 24 to 59 months at the start of the
intervention in August 2008.
Details of statistical procedures used in the study have been
published previously [5]. Briefly, an episode of clinical malaria
was defined as fever or a history of fever in the previous
24 hours together with the presence of at least 5000 asexual
forms of P. falciparum per ml and the absence of any other
obvious cause of fever. WHO’s standard definition was used for
severe malaria [15]. A child was not considered at risk for 21
days if he/she had experienced an episode of malaria and had
been treated with an anti-malarial. The incidence of malaria
was estimated as the number of malaria episodes divided by a
child’s time at risk. Incidence rates of malaria in children who
had received IPTc or placebos during the intervention period
were compared using Cox regression models. Incidence rate
ratios (IRRs) were adjusted for age (used as categorical variable),
sex and village. Confidence intervals around IRRs were
calculated using robust standards errors to account for children
who experienced multiple episodes.
Crude and adjusted IRRs for all-cause and malaria-specific
hospital admissions were also estimated using a Cox regression
model as described above. Prevalence ratios (RRs) of malaria
infection, anaemia (Hb,11 g/dL) and moderately severe anaemia
(Hb,8 g/dL) were estimated using a generalized linear model.
Parasite density and Hb concentrations were compared using
Student’s t-test.
Anthropometric data were analysed as described previously
[5]. Z-scores for weight-for-age (WAZ; underweight), height-for-
age (HAZ; stunting) and weight-for- height (WHZ; wasting)
were determined using the WHO child growth standard [16].
Wasting, stunting and underweight were defined as z-scores,-2
for the relevant indicator. A generalized linear model was fitted
with age, sex and village as covariates to estimate PRs for
wasting, stunting and underweight among children who had
received IPTc compared with those who had received placebos
the previous year.
Table 1. Distribution of children by age, sex and village at the
beginning of the post intervention malaria transmission
season (July 2009).
Intervention Control
N=1416% (n) N=1399% (n)
Age (months)*
6–11 15.1 (214) 17.3 (242)
12–23 22.8 (323) 21.3 (298)
24–35 20.5 (290) 20.4 (285)
36–47 22.9 (324) 20.4 (286)
.= 48 18.7 (265) 20.6 (288)
Sex
Male 52.8 (748) 50.9 (712)
Female 47.2 (668) 49.1 (687)
Villages
Toeghin 25.7 (364) 25.6 (357)
Niou 22.8 (323) 24.2 (339)
Laye 25.7 (364) 25.0 (350)
Sao 25.8 (365) 25.2 (353)
*Age at the time of enrolment (beginning of the trial in August 2008).
doi:10.1371/journal.pone.0023391.t001
Table 2. Effect of IPcT on the incidence of malaria during the post intervention malaria transmission season by age group.
Former Intervention (SP+AQ) Former Control
Episodes
(child years)
Incidence rate
(95%CI)
Episodes
(child years)
Incidence rate
(95%CI)
Unadjusted IRR
(95% CI) P-value
Adjusted*
IRR (95% CI)
Age (months)$
,24 814 (173.1) 4.70 (4.39–5.03) 781 (118.0) 4.38 (4.09–4.71) 1.07 (0.95–1.19) 0.22 1.09 (0.97–1.21) 0.12
$24+ 1020 (304.3) 3.35 (3.15–3.56) 878 (302.5) 2.90 (2.72–3.10) 1.17 (1.05–.29) 0.003 1.16 (1.05–1.28) 0.004
Overall 1834 (477.5) 3.84 (3.67–.02) 1659 (480.7) 3.45 (3.29–3.62) 1.12 (1.04–1.21) 0.004 1.12 (1.04–1.20) 0.003
$Age at the time of enrolment.
*Incidence rate ratios were adjusted for age sex and village using Cox Regression model. Confidence intervals were constructed using robust standard errors to account
lack of independence of malaria episodes in children who experience multiple episodes.
doi:10.1371/journal.pone.0023391.t002
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Results
Characteristic of children at the start of the post
intervention high transmission season
Baseline characteristics of the 1509 and 1505 children
randomized at the beginning of the trial to receive IPTc or
placebos are reported elsewhere [5]. At the beginning of the
post-intervention malaria transmission season (July 2009), 1416
(93.8%) children from the former intervention arm were
available for follow up compared with 1399 (93.0%) children
in the former control arm (Figure 1). Six of the 93 (6.2%)
children from the former intervention arm who were not
available for follow up had died and 87 had migrated out of the
study area. The comparable figures for the 106 children (7.0%)
who had previously received placebos were 11 and 94
respectively; one child who was allergic to SP+AQ was excluded
from the follow-up study. The mean age of children at the start
of post-intervention follow up period was 45.9 months (95%CI
45.3–46.5). The age and sex of children in the two study arms
were similar (Table 1) as was the distribution of children by
village. The proportions of children who were reported to have
slept under a LLIN during weekly home visits were similar
between children who had received IPTc previously and
children who had received placebos (93.1% versus 93.3%).
These proportions of LLIN users are similar to those recorded
during the intervention period.
The effect of IPTc on the incidence of clinical malaria in
the post-intervention malaria transmission season
During the 2009 malaria transmission season (July 2009 to
November 2009), 3493 episodes of malaria were recorded in
study children; 1834 in children who had received IPTc in 2008
and 1659 episodes in those who had received placebos (table 2).
Incidence rates of malaria during this period of high malaria
transmission were 3.84 (95%CI; 3.67–4.02) in children who
had previously received IPTc and 3.45 (95%CI; 3.29–3.62)
episodes in those who had previously received placebos
indicating, a small increase in the incidence of clinical malaria
in the former intervention arm compared to the former control
arm (IRR= 1.12; 95%CI 1.04–1.20) (P = 0.003). A similar
increase in the incidence of malaria was observed when the
analysis covered the whole post intervention period December
2008 to November 2009, including the 2009 dry season,
(IRR= 1.12; (95%CI 1.04–1.20) (P = 0.002) (Table 3). The IRR
for clinical malaria during the post intervention high transmis-
sion season (July–November 2009) was 1.16 (95%CI 1.05–1.28)
(P = 0.004) for children who were aged 24 months or more at
beginning of the intervention and 1.09 (95%CI 0.97–1.21) in
children aged less 24 months at this time. However, there was
not strong evidence that the effect of IPT during the post-
intervention varied with age (P = 0.15). The mean age of
children who experienced a malaria episode during the post
intervention malaria transmission season did not differ between
children who had previously received IPTc and those who
had previously received placebos (39.2 months; 95%CI 38.5–
39.6 versus 38.5 months; 95%CI 37.6–39.3 respectively)
(P = 0.18).
Kaplan-Meier survival plots (Figure 2) for time to first episode of
malaria confirmed that children who had received IPTc in 2008
experienced an increased risk of clinical malaria (P,0.0001)
during the subsequent malaria transmission season compared with
children who had received placebos.
There was no evidence of an increased incidence of malaria
post-intervention in the IPT arm when a malaria episode was
defined as fever or history of fever and the presence of any
parasitaemia (IRR=1.04; 95%CI 0.97–1.10) (P = 0.29).
Table 3. Effect of IPTc on the incidence of malaria during the whole post intervention period (including the dry and rainy seasons)
by age group.
Former Intervention (SP+AQ) Former Control
Episodes
(child years)
Incidence rate
(95%CI)
Episodes
(child years)
Incidence rate
(95%CI)
Unadjusted IRR
(95% CI) P-value
Adjusted*
IRR (95% CI)
Whole post intervention period (December 2008–November 2009)
Age (months)**
,24 849 (497.0) 1.71 (1.60–1.82) 814 (500.1) 1.61 (1.52–1.74) 1.07 (0.96–1.19) 0.24 1.09 (0.97–1.21) 0.13
$24 1106 (822.9) 1.34 (1.26–1.42) 945 (813.2) 1.16 (1.09–.24) 1.17 (1.06–.29) 0..002 1.17 (1.06–1.29) 0.002
Overall 1955 (1320) 1.48 (1.42–.55) 1759 (1312) 1.33 (1.28–1.40) 1.12 (1.04–1.21) 0.003 1.12 (1.04–1.20) 0.002
$Age at the time of enrolment.
*Incidence rate ratios were adjusted for age sex and village using Cox Regression model. Confidence intervals were constructed using robust standard errors to account
lack of independence of malaria episodes in children who experience multiple episodes.
doi:10.1371/journal.pone.0023391.t003
Figure 2. Survival time to first episode of malaria during the
post intervention malaria transmission in children who had
received IPTc or placebo during the previous malaria trans-
mission season.
doi:10.1371/journal.pone.0023391.g002
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Effect of IPTc on hospital admissions in the post-
intervention period
From July 2009 to November 2009, 37 study children who had
received IPTc the previous year were admitted to hospital,
including 19 hospitalisations due to malaria compared with 39
children, 16 with malaria, among those who had previously
received placebos (Table 4). There was no evidence of an increase
in the incidence of all-cause hospital admissions (IRR=0.98;
95%CI 0.61–1.56) (P = 0.93) or hospital admissions due to malaria
(IRR=1.21; 95%CI 0.61–2.43) (P = 0.58) in the children who had
received IPTc previously. Similar findings were observed when
data from the dry season of the post-intervention period were
included in the analysis (Table 5). For the period December 2008
to November 2009, 49 and 52 all-cause hospital admissions were
observed in the former intervention and control arms respectively;
the adjusted IRR was 0.97 (95%CI 0.65–1.47) (P = 0.90). The
numbers of hospital admissions for malaria were 19 and 16 in the
two treatment arms (IRR=1.21; 95%CI 0.61–2.43) (P = 0.58).
There were 8 deaths in each treatment arm during the overall
post-intervention period.
Effect of IPT on malaria infection in the post-intervention
period
Weekly home visits were carried out from July 2009 to
November 2009 to 1495 children in each treatment arm; blood
films were available from 1457 children (97.4%) who had
previously received IPTc and from 1442 (96.4%) children who
had previously received placebos. Five hundred and forty-eight
children (37.6%) in the original IPTc group and 607 (42.1%)
children in the original placebo group were parasitaemic (Table 6).
There was some evidence that children from the former
intervention arm had a lower prevalence of malaria infection
during the post-intervention malaria transmission season than
control children (adjusted PR=0.88 95%CI 0.79–0.98) (P = 0.04).
However, the median parasite density among infected children
was higher in children who had previously received IPTc (5767/
mL; inter quartile range 1141/mL–19091/mL) than in children who
had received placebos (2878/mL; inter quartile range 670/mL–
11837/mL) (P,0.0001).
Of the children who were present at the beginning of the high
malaria transmission season of 2009 (1416 in the former
intervention and 1399 and the control group) 1336 children in
the former intervention arm and 1321 children in the former
control arm participated in the cross-sectional survey at the end of
the 2009 malaria transmission season. Thick and thin blood films
were available from 1324 (99.1%) of children who had previously
received IPT and from 1302 (98.6%) children who had previously
received placebos. Overall, the prevalence of malaria infection
increased with age with children aged 24 months or more being
1.72-fold (95%CI 1.49–2.00) (P,0.001) more likely to carry malaria
infection than their younger siblings. The prevalence of malaria was
40.4% in children from the former IPTc group and 40.1% in
children in the control group (Table 6) (adjusted PR=1.00 95%CI
0.86–1.13) (P= 0.99). As observed during weekly home visits, the
median parasite density was higher in children who had received
IPTc in 2008 than in control children (3059/mL; inter quartile
range 773/mL–9163/mL and 2026/mL; inter quartile range 590/
mL–6640/mL and respectively) (P= 0.006).
Effect of IPT on anaemia in the post intervention period
Hemoglobin concentration was measured at the end of
surveillance in 1324 children who had previously received IPTc
and in 1304 children who had received the placebos. There was no
Table 4. Effect of IPTc on all-cause hospital admissions and hospital admissions for malaria in post intervention malaria
transmission season.
Former Intervention Former Control
Episodes
(child years)
Incidence rate
(95%CI)
Episodes
(child years)
Incidence rate
(95%CI)
Unadjusted IRR
(95% CI) P-value
Adjusted*
IRR (95% CI) P-value
All-cause hospital
admissions
37 (575.2) 0.064
(0.04620.089)
39 (568.6) 0.068
(0.050–0.094)
0.94
(0.60–1.47)
0.78 0.98
(0.61–1.56)
0.93
Hospital admissions
for malaria
19 (576.0) 0.033
(0.021–0.052)
16 (569.7) 0.028
(0.017–0.044)
1.17
(0.60–2.28)
0.47 1.21
(0.61–2.43)
0.58
*Incidence rate ratios were adjusted for age sex and village using Cox Regression model. Confidence intervals were constructed using robust standard errors to account
lack of independence of malaria episodes in children who experience multiple episodes.
doi:10.1371/journal.pone.0023391.t004
Table 5. Effect of IPTc on all-cause hospital admissions and hospital admissions for malaria during the whole post intervention
period, including dry and rainy periods.
Former Intervention Former Control
Episodes
(child years)
Incidence rate
(95%CI)
Episodes
(child years)
Incidence rate
(95%CI)
Unadjusted
IRR (95% CI) P-value
Adjusted*
IRR (95% CI) P-value
All-cause hospital admissions 71 (1844) 0.038 (0.030–
0.049)
93 (1822) 0.051 (0.042–
0.062)
0.75 (0.55–1.03) 0.07 0.78 (0.55–1.09) 0.14
Hospital admissions for malaria 23 (1845) 0.012 (0.008–
0.019
24 (1826) 0.013 (0.009–
0.020)
0.95 (0.53–1.68) 0.86 0.98 (0.55–1.76) 0.95
*Incidence rate ratios were adjusted for age sex and village using Cox Regression model. Confidence intervals were constructed using robust standard errors to account
lack of independence of malaria episodes in children who experience multiple episodes.
doi:10.1371/journal.pone.0023391.t005
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evidence that mean Hb concentration differed between children
from the former intervention and control arms (10.79 g/dL;
95%CI: 10.71 g/dL–10.87 g/dL versus 10.83 g/dL; 95%CI
10.74 g/dL–10.90 g/dL) (P = 0.54) The prevalences of anaemia
(Hb,11 g/dL) and moderately severe anaemia (Hb,8 g/dLl)
were similar in children in the two study arms 678 (51.2%)
compared with 631 (48.4%) and 49 (3.7%) compared with 57
(4.7%) respectively (RR: 1.06 95%CI: 0.95–1.18) (P = 0.29) and
(RR 0.85; 95%CI: 0.58–1.24) (P = 0.40) (Table 6).
Effect of IPT on anthropometric indicators in post-
intervention period
Weight and height were measured at the end of the post-
intervention period in 1336 and 1321 children in former
intervention and control arms respectively; z scores for weight
for age, height for age and weight for height were obtained from
999 children in former intervention arm and from 987 children in
the former control arm (Table 6). The prevalence of wasting was
6.4% in children in the previous IPTc group (64) and 6.3% in the
control children (62). The proportion of children in the previous
IPTc and control arms who were stunted were 38.4% (384) and
39.6% (391) respectively and the proportions of children who were
underweight children were 21.4% (214) and 21.5% (212)
respectively. There was no evidence of an increased in risk of
wasting (P = 0.82), stunting (P = 0.92) or being underweight
(P = 0.30) in children who had previously received IPTc (Table 6).
Discussion
Children previously enrolled in a trial of IPTc with SP+AQ
were followed up for a further 12 months to investigate whether
children who had received IPTc were at increased risk of malaria
(rebound malaria) in the subsequent malaria transmission season
as a consequence of impaired development of acquired immunity
due to reduced exposure to malaria. The study found evidence
that children who had received IPTc during the previous year
experienced a small increase in the incidence of clinical malaria in
the subsequent malaria transmission but there was no shift in the
age at which these children had malaria. In a parallel study in
Mali, which used very similar methods, a similar small increase
(9%; 95%CI: 21–21) was observed [17]. A small, and statistically
non significant, increase (IRR=1.07; 95%CI: 0.90–1.27) had
been reported from an earlier study in children who received SP
bimonthly in Kambila, Mali [3]. Another IPT study in children,
which tested 3 different drug regimens (SP bimonthly, AS+AQ
bimonthly and AS+AQ monthly) in Ghana, reported an excess of
malaria in all treatment groups in the year after intervention was
stopped, but the differences between intervention and placebo
groups were not statistically significant [4].
Previous IPT studies that examined whether IPT was followed
by a ‘rebound’ in malaria were conducted in areas with relatively
low use of ITNs and low malaria transmission intensity. In our
study area malaria transmission is now moderate and 93% of the
children slept under an ITN. This could also interfere with the
development of acquired immunity to malaria [7] although no
direct evidence to support this contention has been found [18].
ITN coverage and malaria transmission intensity differed between
sites. In a forest region of Ghana, where malaria transmission
intensity is higher than in the study area in Burkina Faso, no
evidence of rebound malaria morbidity in children was observed
when IPT with AS+AQ was combined with home management of
malaria [19], a strategy that combines prevention and treatment.
However, there are currently insufficient data to indicate whether
there is an association between levels of malaria transmission and
rebound morbidity.
The effect of IPTc on clinical malaria during the post
intervention year appeared slightly higher in older children who
were likely to have been more exposed to malaria infection in their
lifetime than in their younger siblings. This observation is
consistent with previous reports from Senegal [2] which noted a
greater relative increase in the incidence of malaria in the year
post intervention in older children who had received AS+SP. It is
Table 6. Effect of IPTc on malaria infection, anaemia, and anthropometric indicators during the post intervention period.
Former intervention (SP
+AQ) Former control Unadjusted analysis Adjusted analysis
% (n) N % (n) N
Prevalence ratio
(95%CI) P-value
Prevalence ratio*
(95% CI) P-value
Prevalence of malaria infection during the post intervention period (weekly surveys)
Proportion with parasitaemia 37.6 (548) 1457 42.1 (607) 1442 0.89 (0.82–0.98) 0.014 0.88 (0.79–0.98) 0.039
Prevalence of malaria infection at the end of post intervention malaria transmission season
Proportion with parasitaemia 40.4 (535) 1324 40.1 (522) 1302 1.00 (0.92–1.10) 0.98 1.00 (0.86–1.13) 0.99
Prevalence of anaemia at the end of the post intervention malaria transmission season
Anaemia (Hb,11 g/dl) 51.2 (678) 1324 48.4 (631) 1304 1.06 (0.98–1.14) 0.15 1.06 (0.95–1.18) 0.29
Moderately severe anaemia
(Hb,8 g/dl)
3.7 (49) 1324 4.7 (57) 1304 0.86 (0.57–1.28) 0.38 0.85 (0.58–1.24) 0.40
Prevalence of wasting, stunting and being underweight at the end of post intervention malaria transmission season
$Wasting 6.4 (64) 928 6.3 (62) 998 1.02 (0.71–1.47) 0.90 1.04 (0.72–1.51) 0.82
{Stunting 38.4 (384) 999 39.6 (391) 987 0.99 (0.82–1.19) 0.92 0.95 (0.79–1.14) 0.92
{Underweight 21.4 (214) 999 21.5 (212) 987 0.99 (0.80–1.23) 0.97 0.84 (0.60–1.17) 0.30
*Prevalence ratios adjusted for age, sex and village using a generalized linear model (GLM).
$Wasting was defined as,22 z score weight for age.
{Stunting was define as,22 z score of height for age.
{Underweight was defined as,22 z score of weight for height.
doi:10.1371/journal.pone.0023391.t006
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worth noting that the number of children who still aged less than
24 months in our study was relatively small in the post intervention
year; the study was only powered to detect a 20% excess in clinical
malaria in children (younger and older children combined). In
addition, a test for interaction found no evidence that the effect of
IPTc on clinical malaria during the post intervention year varied
with age. In contrast, a significantly higher increase in the
incidence of malaria was observed in younger children (3–11
months at enrolment) than in older children (12–59 months) who
received AS+AQ monthly in Ghana [4]. Our study did not
demonstrate persisting protection in younger children during the
high malaria transmission period post intervention as was the case
in Senegal [2].
The small excess of clinical malaria in the post intervention
period in children in the former intervention arm was not
accompanied by an increase in all-cause hospital admissions or
hospital admissions due to malaria. However, our study was not
powered to detect a rebound effect in hospital admission, and
caution is required in the interpretation of these results.
Children who had received IPTc during the previous year were
not at increased risk of harbouring a malaria infection at the end of
the subsequent malaria transmission season nor did they have a
higher prevalence of malaria infection during weekly surveys,
despite their slightly increased susceptibility to clinical malaria.
Although children who had received IPT in 2008 appeared to
have lower prevalence of malaria infection in the subsequent
malaria transmission season than control children, they had a
reduced ability to control parasite density which is important for
the development of clinical malaria, and may partially explain the
slight increase in clinical malaria. Similar findings have been
observed previously in children [2,4] and infants [11] who have
received IPT. High parasitaemia is an important risk factor for
malaria anaemia. However, in this study, children who had
received IPTc were not at an increased risk of anaemia or
moderately severe anemia at the end of the subsequent malaria
transmission season. This finding is consistent with previous
reports on from Senegal [2] and Ghana [4,19].
A limitation of this study, and previous studies that examined
the role of IPTc in causing rebound malaria morbidity, is that the
intervention was given during only one malaria transmission
season. This may not be sufficient to significantly impair the
acquisition of immunity and induce a large increase in malaria
morbidity. In addition, most of these children enrolled in the
studies undertaken so far had experienced significant exposure to
malaria infection prior to the intervention and may, therefore,
have developed some level of immunity to malaria before receiving
IPTc which may have been sufficient to counterbalance the
potential negative effects of reduced exposure to malaria on
malaria morbidity in the subsequent transmission season. If IPTc
is to be deployed on a major scale and given annually for the first
few years of a child’s life, it will be essential that the impact of
several years of IPTc on the development of immunity to malaria
is investigated carefully.
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